Literature DB >> 22822062

Biochemical characterization of human tyrosyl-DNA phosphodiesterase 2 (TDP2/TTRAP): a Mg(2+)/Mn(2+)-dependent phosphodiesterase specific for the repair of topoisomerase cleavage complexes.

Rui Gao1, Shar-yin N Huang, Christophe Marchand, Yves Pommier.   

Abstract

TDP2 is a multifunctional enzyme previously known for its role in signal transduction as TRAF and TNF receptor-associated protein (TTRAP) and ETS1-associated protein 2 (EAPII). The gene has recently been renamed TDP2 because it plays a critical role for the repair of topoisomerase II cleavage complexes (Top2cc) and encodes an enzyme that hydrolyzes 5'-tyrosine-DNA adducts that mimic abortive Top2cc. Here we further elucidate the DNA-processing activities of human recombinant TDP2 and its biochemical characteristics. The preferred substrate for TDP2 is single-stranded DNA or duplex DNA with a four-base pair overhang, which is consistent with the known structure of Top2cc or Top3cc. The k(cat)/K(m) of TDP1 and TDP2 was determined. It was found to be 4 × 10(5) s(-1)M(-1) for TDP2 using single-stranded 5'-tyrosyl-DNA. The processing of substrates as short as five nucleotides long suggests that TDP2 can directly bind DNA ends. 5'-Phosphodiesterase activity requires a phosphotyrosyl linkage and tolerates an extended group attached to the tyrosine. TDP2 requires Mg(2+) or Mn(2+) for efficient catalysis but is weakly active with Ca(2+) or Zn(2+). Titration with Ca(2+) demonstrates a two-metal binding site in TDP2. Sequence alignment suggests that TDP2 contains four conserved catalytic motifs shared by Mg(2+)-dependent endonucleases, such as APE1. Substitutions at each of the four catalytic motifs identified key residues Asn-120, Glu-152, Asp-262, and His-351, whose mutation to alanine significantly reduced or completely abolished enzymatic activity. Our study characterizes the substrate specificity and kinetic parameters of TDP2. In addition, a two-metal catalytic mechanism is proposed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22822062      PMCID: PMC3436327          DOI: 10.1074/jbc.M112.393983

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  44 in total

Review 1.  DNA topoisomerases and their poisoning by anticancer and antibacterial drugs.

Authors:  Yves Pommier; Elisabetta Leo; HongLiang Zhang; Christophe Marchand
Journal:  Chem Biol       Date:  2010-05-28

2.  Development of a novel assay for human tyrosyl DNA phosphodiesterase 2.

Authors:  Sanjay Adhikari; Soumendra K Karmahapatra; Hadi Elias; Priyanka Dhopeshwarkar; R Scott Williams; Stephen Byers; Aykut Uren; Rabindra Roy
Journal:  Anal Biochem       Date:  2011-05-12       Impact factor: 3.365

3.  Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide.

Authors:  Chyuan-Chuan Wu; Tsai-Kun Li; Lynn Farh; Li-Ying Lin; Te-Sheng Lin; Yu-Jen Yu; Tien-Jui Yen; Chia-Wang Chiang; Nei-Li Chan
Journal:  Science       Date:  2011-07-22       Impact factor: 47.728

4.  I-TASSER: a unified platform for automated protein structure and function prediction.

Authors:  Ambrish Roy; Alper Kucukural; Yang Zhang
Journal:  Nat Protoc       Date:  2010-03-25       Impact factor: 13.491

5.  Characterization of the endoribonuclease active site of human apurinic/apyrimidinic endonuclease 1.

Authors:  Wan-Cheol Kim; Brian R Berquist; Manbir Chohan; Christopher Uy; David M Wilson; Chow H Lee
Journal:  J Mol Biol       Date:  2011-07-06       Impact factor: 5.469

Review 6.  Interfacial inhibitors: targeting macromolecular complexes.

Authors:  Yves Pommier; Christophe Marchand
Journal:  Nat Rev Drug Discov       Date:  2011-12-16       Impact factor: 84.694

7.  The PML nuclear bodies-associated protein TTRAP regulates ribosome biogenesis in nucleolar cavities upon proteasome inhibition.

Authors:  S Vilotti; M Biagioli; R Foti; M Dal Ferro; Z Scotto Lavina; L Collavin; G Del Sal; S Zucchelli; S Gustincich
Journal:  Cell Death Differ       Date:  2011-09-16       Impact factor: 15.828

8.  TDP2/TTRAP is the major 5'-tyrosyl DNA phosphodiesterase activity in vertebrate cells and is critical for cellular resistance to topoisomerase II-induced DNA damage.

Authors:  Zhihong Zeng; Felipe Cortés-Ledesma; Sherif F El Khamisy; Keith W Caldecott
Journal:  J Biol Chem       Date:  2010-10-28       Impact factor: 5.157

9.  Oncogenic role of EAPII in lung cancer development and its activation of the MAPK-ERK pathway.

Authors:  C Li; S Fan; T K Owonikoko; F R Khuri; S-Y Sun; R Li
Journal:  Oncogene       Date:  2011-04-11       Impact factor: 9.867

10.  The DNA binding and 3'-end preferential activity of human tyrosyl-DNA phosphodiesterase.

Authors:  Thomas S Dexheimer; Andrew G Stephen; Matthew J Fivash; Robert J Fisher; Yves Pommier
Journal:  Nucleic Acids Res       Date:  2010-01-21       Impact factor: 16.971

View more
  37 in total

Review 1.  Tyrosyl-DNA-phosphodiesterases (TDP1 and TDP2).

Authors:  Yves Pommier; Shar-yin N Huang; Rui Gao; Benu Brata Das; Junko Murai; Christophe Marchand
Journal:  DNA Repair (Amst)       Date:  2014-05-22

2.  Discovery of potent indenoisoquinoline topoisomerase I poisons lacking the 3-nitro toxicophore.

Authors:  Daniel E Beck; Monica Abdelmalak; Wei Lv; P V Narasimha Reddy; Gabrielle S Tender; Elizaveta O'Neill; Keli Agama; Christophe Marchand; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2015-04-24       Impact factor: 7.446

3.  Biochemical assays for the discovery of TDP1 inhibitors.

Authors:  Christophe Marchand; Shar-yin N Huang; Thomas S Dexheimer; Wendy A Lea; Bryan T Mott; Adel Chergui; Alena Naumova; Andrew G Stephen; Andrew S Rosenthal; Ganesha Rai; Junko Murai; Rui Gao; David J Maloney; Ajit Jadhav; William L Jorgensen; Anton Simeonov; Yves Pommier
Journal:  Mol Cancer Ther       Date:  2014-07-14       Impact factor: 6.261

4.  Novel deazaflavin tyrosyl-DNA phosphodiesterase 2 (TDP2) inhibitors.

Authors:  Evgeny Kiselev; Azhar Ravji; Jayakanth Kankanala; Jiashu Xie; Zhengqiang Wang; Yves Pommier
Journal:  DNA Repair (Amst)       Date:  2019-11-06

5.  Synthesis and biological evaluation of new fluorinated and chlorinated indenoisoquinoline topoisomerase I poisons.

Authors:  Daniel E Beck; Wei Lv; Monica Abdelmalak; Caroline B Plescia; Keli Agama; Christophe Marchand; Yves Pommier; Mark Cushman
Journal:  Bioorg Med Chem       Date:  2016-02-09       Impact factor: 3.641

6.  Epigenetic and genetic inactivation of tyrosyl-DNA-phosphodiesterase 1 (TDP1) in human lung cancer cells from the NCI-60 panel.

Authors:  Rui Gao; Benu Brata Das; Raghunath Chatterjee; Ogan D Abaan; Keli Agama; Renata Matuo; Charles Vinson; Paul S Meltzer; Yves Pommier
Journal:  DNA Repair (Amst)       Date:  2013-12-16

7.  New fluorescence-based high-throughput screening assay for small molecule inhibitors of tyrosyl-DNA phosphodiesterase 2 (TDP2).

Authors:  Carlos J A Ribeiro; Jayakanth Kankanala; Ke Shi; Kayo Kurahashi; Evgeny Kiselev; Azhar Ravji; Yves Pommier; Hideki Aihara; Zhengqiang Wang
Journal:  Eur J Pharm Sci       Date:  2018-03-21       Impact factor: 4.384

8.  Mitochondrial tyrosyl-DNA phosphodiesterase 2 and its TDP2S short isoform.

Authors:  Shar-Yin N Huang; Ilaria Dalla Rosa; Stephanie A Michaels; David V Tulumello; Keli Agama; Salim Khiati; Sae Rin Jean; Simone A Baechler; Valentina M Factor; Sudhir Varma; Junko Murai; Lisa M Miller Jenkins; Shana O Kelley; Yves Pommier
Journal:  EMBO Rep       Date:  2018-02-09       Impact factor: 8.807

Review 9.  Drugging topoisomerases: lessons and challenges.

Authors:  Yves Pommier
Journal:  ACS Chem Biol       Date:  2013-01-04       Impact factor: 5.100

10.  Proteolytic degradation of topoisomerase II (Top2) enables the processing of Top2·DNA and Top2·RNA covalent complexes by tyrosyl-DNA-phosphodiesterase 2 (TDP2).

Authors:  Rui Gao; Matthew J Schellenberg; Shar-Yin N Huang; Monica Abdelmalak; Christophe Marchand; Karin C Nitiss; John L Nitiss; R Scott Williams; Yves Pommier
Journal:  J Biol Chem       Date:  2014-05-07       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.